Epidermal growth factor (EGF) is upregulated in approximately 60% of adenocarcinomas of the pancreas, providing a rationale for the use of EGFR inhibitors in pancreatic carcinoma [16, 17]. Here, EGF is linked to pancreatic adenocarcinoma.